<VariationArchive VariationID="2736883" VariationName="NM_000540.3(RYR1):c.10946dup (p.Cys3650fs)" VariationType="Duplication" Accession="VCV002736883" Version="2" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-05-19" DateCreated="2024-02-14" MostRecentSubmission="2024-04-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2905453" VariationID="2736883">
      <GeneList>
        <Gene Symbol="RYR1" FullName="ryanodine receptor 1" GeneID="6261" HGNC_ID="HGNC:10483" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19q13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="38433691" stop="38587564" display_start="38433691" display_stop="38587564" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="38924339" stop="39078203" display_start="38924339" display_stop="39078203" Strand="+" />
          </Location>
          <OMIM>180901</OMIM>
          <Haploinsufficiency last_evaluated="2015-11-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RYR1">No evidence available</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2015-11-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RYR1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000540.3(RYR1):c.10946dup (p.Cys3650fs)</Name>
      <CanonicalSPDI>NC_000019.10:38528606:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>19q13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="38528606" stop="38528607" display_start="38528606" display_stop="38528607" variantLength="1" positionVCF="38528606" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="39019246" stop="39019247" display_start="39019246" display_stop="39019247" variantLength="1" positionVCF="39019246" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>C3645fs</ProteinChange>
      <ProteinChange>C3650fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.10" sequenceAccession="NC_000019" sequenceVersion="10" change="g.38528607dup" Assembly="GRCh38">
            <Expression>NC_000019.10:g.38528607dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.39019247dup" Assembly="GRCh37">
            <Expression>NC_000019.9:g.39019247dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008866.1" sequenceAccession="NG_008866" sequenceVersion="1" change="g.99908dup">
            <Expression>NG_008866.1:g.99908dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000540.3" sequenceAccession="NM_000540" sequenceVersion="3" change="c.10946dup" MANESelect="true">
            <Expression>NM_000540.3:c.10946dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000531.2" sequenceAccession="NP_000531" sequenceVersion="2" change="p.Cys3650fs">
            <Expression>NP_000531.2:p.Cys3650fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001042723.2" sequenceAccession="NM_001042723" sequenceVersion="2" change="c.10931dup">
            <Expression>NM_001042723.2:c.10931dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001036188.1" sequenceAccession="NP_001036188" sequenceVersion="1" change="p.Cys3645fs">
            <Expression>NP_001036188.1:p.Cys3645fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_766" sequenceAccession="LRG_766">
            <Expression>LRG_766:g.99908dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_766t1" sequenceAccession="LRG_766t1">
            <Expression>LRG_766t1:c.10946dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_766p1" sequenceAccession="LRG_766p1" change="p.Cys3650Metfs">
            <Expression>LRG_766p1:p.Cys3650Metfs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000540.3(RYR1):c.10946dup (p.Cys3650fs) AND RYR1-related disorder" Accession="RCV003593338" Version="1">
        <ClassifiedConditionList TraitSetID="33623">
          <ClassifiedCondition DB="MedGen" ID="CN239331">RYR1-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-03-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000540.3(RYR1):c.10946dup (p.Cys3650fs) AND Malignant hyperthermia, susceptibility to, 1" Accession="RCV004011417" Version="2">
        <ClassifiedConditionList TraitSetID="3539">
          <ClassifiedCondition DB="MedGen" ID="C2930980">Malignant hyperthermia, susceptibility to, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-06-08" SubmissionCount="1">Uncertain significance</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-06-08" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2024-02-14" MostRecentSubmission="2024-04-20">
        <ReviewStatus>criteria provided, conflicting classifications</ReviewStatus>
        <Description>Conflicting classifications of pathogenicity</Description>
        <Explanation DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(1)</Explanation>
        <Citation Type="general">
          <ID Source="PubMed">23919265</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25960145</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28818389</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30611313</ID>
        </Citation>
        <Comment DataSource="ClinVar" Type="public">Pathogenic(1); Uncertain significance(1)</Comment>
        <DescriptionHistory Dated="2024-04-19">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="3539" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2639" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Anesthesia related hyperthermia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant hyperpyrexia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fulminating hyperpyrexia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Pharmacogenic myopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant hyperthermia suceptibility 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant hyperthermia, susceptibility to, 1</ElementValue>
                <XRef ID="MONDO:0007783" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MHS1</ElementValue>
                <XRef Type="MIM" ID="145600" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are precipitated by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine). The triggering substances cause uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase (CK) concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure. In nearly all cases, the first manifestations of MH (tachycardia and tachypnea) occur in the operating room; however, MH may also occur in the early postoperative period. There is mounting evidence that some individuals with MHS will also develop MH with exercise and/or on exposure to hot environments. Without proper and prompt treatment with dantrolene sodium, mortality is extremely high.</Attribute>
                <XRef ID="NBK1146" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3363" />
                <XRef ID="3363" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Pharmacogenetic</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="EMHG, 2018">
                <ID Source="PubMed">33131754</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301325</ID>
                <ID Source="BookShelf">NBK1146</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2011">
                <ID Source="pmc">3110041</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Sei et al., 2004">
                <ID Source="PubMed">14870754</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_MalignantHyperthermia-enPro649.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Malignant hyperthermia</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Malignant-Hyperthermia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, RYR1 and CACNA1S Pathogenic Variants (Malignant Hyperthermia), 2019</CitationText>
              </Citation>
              <XRef ID="423" DB="Orphanet" />
              <XRef ID="C2930980" DB="MedGen" />
              <XRef ID="MONDO:0007783" DB="MONDO" />
              <XRef Type="MIM" ID="145600" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33623" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36528" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">RYR1-related disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">RYR1-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">RYR1-Related Disorders</ElementValue>
              </Name>
              <XRef ID="CN239331" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7983687" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2024-02-14">
        <ClinVarSubmissionID localKey="4956213|MedGen:CN239331" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004297342" DateUpdated="2024-02-14" DateCreated="2024-02-14" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-03-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23919265</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25960145</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28818389</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30611313</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28818389</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Cys3650Metfs*2) in the RYR1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RYR1 are known to be pathogenic (PMID: 23919265, 25960145, 28818389, 30611313). For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with autosomal recessive RYR1-related myopathy (PMID: 28818389). This variant is not present in population databases (gnomAD no frequency).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RYR1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.39019246_39019247insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN239331" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14200283</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9017375" SubmissionDate="2024-04-16" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="1039674|MONDO:0007783" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004830245" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="All of Us Research Program, National Institutes of Health" OrgID="509529" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-06-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Uncertain Significance</GermlineClassification>
          <Comment>This variant inserts 1 nucleotide in exon 75 of the RYR1 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. To our knowledge, this variant has not been reported in individuals affected with RYR1-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of RYR1 function due to truncation variants is not an established disease mechanism for autosomal dominant malignant hyperthermia, although it is associated with other phenotype(s) (https://clinicalgenome.org/). Due to insufficient evidence, this variant is classified as a Variant of Uncertain Significance for autosomal dominant malignant hyperthermia.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>108544</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RYR1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.39019247dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007783" />
          </Trait>
        </TraitSet>
        <Comment>This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB14382316</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7983687" TraitType="Disease" MappingType="XRef" MappingValue="CN239331" MappingRef="MedGen">
        <MedGen CUI="CN239331" Name="RYR1-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9017375" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007783" MappingRef="MONDO">
        <MedGen CUI="C2930980" Name="Malignant hyperthermia, susceptibility to, 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

